We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.01B
AUM Growth
-$490M
Cap. Flow
-$415M
Cap. Flow %
-40.98%
Top 10 Hldgs %
28.64%
Holding
97
New
5
Increased
11
Reduced
69
Closed
8

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18M
2
BNTX icon
BioNTech
BNTX
+$14.3M
3
ALGN icon
Align Technology
ALGN
+$7.3M
4
GDRX icon
GoodRx Holdings
GDRX
+$5.39M
5
CYTK icon
Cytokinetics
CYTK
+$5.15M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$29.9M
2
PFE icon
Pfizer
PFE
+$24.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$23.8M
4
ELV icon
Elevance Health
ELV
+$23.7M
5
MCK icon
McKesson
MCK
+$22.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Industrials 1.09%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
51
MeiraGTx Holdings
MGTX
$1.2B
$6.92M 0.68%
500,000
+50,000
+11% +$770K
IMGN
52
DELISTED
Immunogen Inc
IMGN
$6.78M 0.67%
1,425,000
-75,000
-5% -$415K
TDOC icon
53
Teladoc Health
TDOC
$1.25B
$6.64M 0.65%
92,000
-33,000
-26% -$2.38M
GH icon
54
Guardant Health
GH
$22.2B
$6.29M 0.62%
95,000
-105,000
-53% -$7.19M
SILK
55
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.19M 0.61%
150,000
-50,000
-25% -$1.76M
GKOS icon
56
Glaukos
GKOS
$10.8B
$6.09M 0.6%
105,291
-69,709
-40% -$3.69M
NVCR icon
57
NovoCure
NVCR
$2.03B
$5.78M 0.57%
69,700
-50,687
-42% -$3.73M
AERI
58
DELISTED
Aerie Pharmaceuticals
AERI
$5.36M 0.53%
589,200
-160,800
-21% -$1.24M
EXAS
59
DELISTED
Exact Sciences
EXAS
$5.31M 0.52%
76,000
-34,000
-31% -$2.49M
PGNY icon
60
Progyny
PGNY
$2.05B
$5.14M 0.51%
100,000
-1,262
-1% -$54K
IMCR icon
61
Immunocore
IMCR
$1.75B
$5.1M 0.5%
170,472
+80,472
+89% +$2.03M
ALKS icon
62
Alkermes
ALKS
$8.3B
$4.74M 0.47%
180,000
-30,000
-14% -$743K
HCAT icon
63
Health Catalyst
HCAT
$135M
$4.7M 0.46%
180,000
-60,000
-25% -$1.7M
ESPR
64
DELISTED
Esperion Therapeutics
ESPR
$4.55M 0.45%
981,582
-18,418
-2% -$79K
GDRX icon
65
GoodRx Holdings
GDRX
$1.31B
$4.54M 0.45%
+235,000
New +$5.39M
SGMO
66
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.42M 0.44%
761,429
-3,571
-0.5% -$21.2K
ISEE
67
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.38M 0.43%
260,000
-90,000
-26% -$1.33M
ONEM
68
DELISTED
1Life Healthcare
ONEM
$4.16M 0.41%
375,250
-154,750
-29% -$1.73M
OSH
69
DELISTED
Oak Street Health, Inc.
OSH
$4.03M 0.4%
150,000
-70,000
-32% -$1.48M
RVNC
70
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.87M 0.38%
+198,358
New +$3.01M
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$773M
$3.82M 0.38%
127,777
-24,223
-16% -$656K
NTLA icon
72
Intellia Therapeutics
NTLA
$1.68B
$3.63M 0.36%
+50,000
New +$4.24M
ACCD
73
DELISTED
Accolade Inc
ACCD
$3.51M 0.35%
200,000
-10,000
-5% -$184K
MYOV
74
DELISTED
Myovant Sciences Ltd.
MYOV
$3.32M 0.33%
249,300
-700
-0.3% -$9.39K
NKTR icon
75
Nektar Therapeutics
NKTR
$2.53B
$3.31M 0.33%
40,926
-22,407
-35% -$3.32M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rhenman & Partners Asset Management held 97 positions worth $1.01B, down 33% from $1.5B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $415M in Q1 2022, closing 8 positions and reducing 69 holdings. Its most notable exit was HCA Healthcare, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Regeneron Pharmaceuticals worth $19.9M.

  • Rhenman & Partners Asset Management's largest Q1 2022 buy was Regeneron Pharmaceuticals: 28,500 shares worth $19.9M.
  • Rhenman & Partners Asset Management added most to Align Technology in Q1 2022, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2022 reduction was UnitedHealth, cutting an estimated $29.9M.
  • Rhenman & Partners Asset Management fully exited HCA Healthcare in Q1 2022, selling an estimated $15.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.01B portfolio in Q1 2022.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 8 in Q1 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 33% quarter-over-quarter to $1.01B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.